K Health vs Wisp
An in-depth comparison of two leading GLP-1 Providers
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
K Health
Best for users who want general primary care with GLP-1 prescribing as one available option, not a single-condition weight-loss funnelStarting at $300/mo
Wisp
Best for buyers who want a board-certified telehealth platform offering both branded injectables AND a sublingual alternative — with full disclosure that the sublingual form is not human-testedStarting at $225/mo
Side-by-Side Comparison
| Feature | K Health | Wisp |
|---|---|---|
| Overall Score | 6.6/10 | ✓7.0/10 |
| Starting Price | $300/mo | ✓$225/mo |
| Editorial Rating | 3.3 ★ /5 | ✓3.5 ★ /5 |
| Features | 4 features | ✓6 features |
| States Available | 0 | 0 |
| Compounded | — | ✓ Yes |
| Brand Name | ✓ Yes | — |
| FSA/HSA Accepted | — | — |
| FDA Warnings | None | None |
Pros & Cons
K Health
Pros
- ✓Established US telehealth with health-system integrations (Cedars-Sinai, Hartford HealthCare, Hackensack Meridian)
- ✓AI intake reduces upfront friction for users who don't want to sit through a long questionnaire before seeing a clinician
- ✓Primary-care relationship rather than a single-condition funnel — useful for users who want one provider managing multiple conditions
Cons
- ✗Not a GLP-1 specialty platform — weight management is ancillary to primary care, and GLP-1 prescribing is clinician-discretionary at the visit level
- ✗Pricing for GLP-1 specifically is not displayed publicly — needs direct confirmation from K Health support before placing readers
- ✗States served list and pharmacy partners are not publicly enumerated
Wisp
Pros
- ✓Wider GLP-1 menu than the prior stub suggested — both branded injectables (Wegovy, Zepbound, Saxenda) AND the compounded sublingual option
- ✓LegitScript certified, board-certified providers (Dr. Shannon Chatham DO, Andrea Sleeth WHNP-BC publicly named)
- ✓Wisp's product page uses appropriately cautious language around sublingual: 'lab tests using human-derived tissues suggest it may begin working' and 'effectiveness in patients may vary' — disclosure is more rigorous than most compounded GLP-1 marketing
Cons
- ✗EFFECTIVENESS CAVEAT: sublingual compounded semaglutide has not been tested in humans — Wisp's own product page explicitly states this. Injectables (Wegovy, Zepbound, Saxenda) on the same platform have FDA safety/efficacy data; sublingual does not.
- ✗Pharmacy partners not publicly named
- ✗States served list not publicly enumerated
Our Verdict
Wisp edges out K Health with a higher overall score of 7.0/10 and is particularly strong for buyers who want a board-certified telehealth platform offering both branded injectables AND a sublingual alternative — with full disclosure that the sublingual form is not human-tested. K Health remains a solid alternative, especially if you're looking for users who want general primary care with GLP-1 prescribing as one available option, not a single-condition weight-loss funnel.
Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.